Critic at Large

» publishing, funding and regulation

Most Recent

image: Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy

Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy

By | February 1, 2017

What can be done to lower development costs and drug prices?

4 Comments

image: Getting Animal Research Right

Getting Animal Research Right

By | March 1, 2016

Regulatory and compliance expectations for animal-based research are demanding, while public and political scrutiny of animal research is rising.

2 Comments

image: Defending Against Plagiarism

Defending Against Plagiarism

By | June 1, 2013

Publishers need to be proactive about detecting and deterring copied text.

5 Comments

image: DIYbio: Low Risk, High Potential

DIYbio: Low Risk, High Potential

By | March 1, 2013

Citizen scientists can inspire innovation and advance science education—and they are proving adept at self-policing.

5 Comments

image: Regulating Amateurs

Regulating Amateurs

By | March 1, 2013

How should the government ensure the safety and responsibility of do-it-yourself biologists?

2 Comments

image: Bring On the Transparency Index

Bring On the Transparency Index

By | August 1, 2012

Grading journals on how well they share information with readers will help deliver accountability to an industry that often lacks it.

6 Comments

image: Predatory Publishing

Predatory Publishing

By | August 1, 2012

Overzealous open-access advocates are creating an exploitative environment, threatening the credibility of scholarly publishing.

32 Comments

image: All’s Not Fair in Science and Publishing

All’s Not Fair in Science and Publishing

By | July 1, 2012

False credit for scientific discoveries threatens the success and pace of research.

72 Comments

image: Food for Thought

Food for Thought

By | June 1, 2012

Plant research remains grossly underfunded, despite the demand for increased crop production to support a growing population.

6 Comments

image: Regulations for Biosimilars

Regulations for Biosimilars

By | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

Popular Now

  1. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  2. An Aging-Related Effect on the Circadian Clock
  3. Marching for Science, from Berlin to Sydney
  4. Abundant Sequence Errors in Public Databases
Business Birmingham